Studies Suggest Once-Daily Combination Therapy Of Doravirine, Islatravir Is Noninferior To Current, Baseline Suppressive Therapies Among Adults With HIV

Healio (3/17, Stulpin) reports, “Data from two studies suggest that a once-daily combination therapy of doravirine [DOR] and islatravir [ISL] was noninferior to current, baseline suppressive therapies among adults with HIV.” One researcher said, “These two large, global pivotal trials of the two-drug combination of DOR and ISL achieved positive efficacy and safety results at the primary endpoint in a virologically suppressed population of people living with HIV. ... The trials support ongoing development of islatravir as a component of long-acting two-drug regimens.” The studies’ findings were presented at the Conference on Retroviruses and Opportunistic Infections.